HTFLHeartflow, Inc.

Healthcare

$49.71+51% 1Y

$49.71

$20.4952 weeks$52.16

Price

+51%1Y

End-of-day closes, not the intraday tick.

More going right than wrong

Quality mixed, nothing alarming, growing in the filings, the market undecided.

What they do

We provide software and artificial intelligence (“AI”) designed to deliver a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease (“CAD”), a leading cause of death worldwide. As of December 31, 2025, our Heartflow Platform has been used to assess CAD in more than 600,000 patients, including 219,000 in 2025 alone. We believe that we are the most widely adopted AI-powered test for CAD.

In the company’s own words · 10-K filed Mar 18, 2026 · SEC EDGAR

P/En/a

Market value$3.02B

1 year+51%

5 yearsn/a

Charts

As reported to the SEC, without any scoring.

Heartflow, Inc. (HTFL) reported revenue of $64M in Q2 2026 (quarter ended Jun 30, 2026), up 48% from the same quarter a year earlier. That came with a gross margin of 83% and net loss of $16M. For the full year FY2025, revenue was $176M (+40% year on year) and net income −$117M. Its largest region in Q3 2025 (quarter ended Sep 30, 2025) was United States at $43M, 93% of the disclosed total, well ahead of United Kingdom at 3.3%. The next results filing is expected around Nov 11, 2026, the same week as a year ago.

What the company said

The company's own words from its current reports to the SEC, newest first

Aug 13, 2026Heartflow Reports Second Quarter 202 6 Financial Results and Raises Full Year 2026 Guidance.Earnings release · press release
May 14, 2026Heartflow Reports F irst Quarter 202 6 Financial Results and Raises Full Year 2026 Guidance.Earnings release · press release
Mar 18, 2026Heartflow Reports Fourth Quarter and Full Year 2025 Financial Results.Earnings release · press release